田晨，副主任醫(yī)師，副教授，碩士研究生導(dǎo)師，醫(yī)學(xué)博士。天津抗癌協(xié)會老年腫瘤專業(yè)委員會委員，國家自然科學(xué)基金初審評審專家，2016年入選天津腫瘤醫(yī)院十三五“優(yōu)秀青年創(chuàng)新人才”，2015年入選天津市“131”創(chuàng)新人才第三層次。2017年入選天津市“131”創(chuàng)新人才第二層次。研究成果“造血干細胞病理狀態(tài)下調(diào)控機制及關(guān)鍵分子靶點”獲得2015年教育部自然科學(xué)二等獎。發(fā)明專利：抗人HER2單克隆抗體檢測試劑盒。2012年因“Distinct effects of SCF and Hes1 on normal hematopoietic stem and progenitor cells during leukemic cell expansion in a T-ALL mouse model”獲美國血液協(xié)會的Abstract Achievement Award。擔(dān)任《Tumor Biology》，《Oncotargets and therapy》，《Annals of Hematology》，《Oncotarget》，《中國實驗血液學(xué)》等雜志審稿人。發(fā)表中英文文章50余篇，累計影響因子50多分。 　　文章 　　1. Tian C, Zheng G, Zhuang H, Li X, Hu D, Zhu L, Wang T, You M.James, Zhang Y. MicroRNA-494 Activation Suppresses Bone Marrow Stromal Cell-Mediated Drug Resistance in Acute Myeloid Leukemia Cells. Journal of Cellular Physiology. 2017; 232(6): 1387-1395. 　　2. Tian C, Yang H, Zhu L, Zhang Q, Cao Z, Zhang Y. Anti-CD138 chimeric antigen receptor-modified T-cell therapy for multiple myeloma with extensive extramedullary involvement. Ann Hematol. 2017; 96(8), 1407-1410共同通訊DOI 10.1007/s00277-017-3029-3 　　3. Tian C, Wang X, Zhang Y. Glomerular infiltration by intravascular large B-cell lymphoma. Br J Haematol. 2016；174(6): 833. 　　4. Tian C, Zhang Y. Purification of hematopoietic stem cells from bone marrow. Ann Hematol. 2016; 95(4): 543-7. 　　5. Tian C, You MJ, Yu Y, Zhu L, Zheng G, Zhang Y. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1. Tumour Biol. 2016; 37(6): 7461-71. 　　6. Tian C, Yu Y, Yang H, Zhu L, Wang Y, Zhang Y. ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy. OncoTargets and Therapy. 2016: 9: 265-268 　　7. Wang C, Tian C, Zhang Y. The interaction between niche and hematopoietic stem cells. Indian J Hematol Blood Transfus. 2016; 32(4): 377-382.共同通訊 　　8. Xia B, Yuan T, Tian C, Li Q, Tang Y, Yang H, Wang Y, Yu Y, Zhang Y. Role of CXCR4/STAT3 pathway in mesenchymal stromal cell-mediated drug resistance of acute leuke

分子靶向治療等綜合性治療和個體化治療。擅長惡性淋巴瘤、多發(fā)性骨髓瘤、白血病等的診斷和治療。